A Study of NINLARO® in Chinese Adults With Multiple Myeloma

Inclusion Criteria:

1. Who was first diagnosed or first relapse MM participants using IMWG 2016 criteria.

2. Diagnosed with multiple myeloma using IMWG 2016 criteria and must be transplantineligible as determined by their physician, or if transplant eligible, not expectto undergo transplant for at least 24 months after study enrollment. a. Stem cell harvest and mobilization regimen is acceptable if clinically indicated.But must first be confirmed by the Takeda Medical Monitor.

3. Who received bortezomib/carfilzomib-based triple-drug regimens as frontlinetreatment, including bortezomib+cyclophosphamide+dexamethasone (VCD),bortezomib+lenalidomide dexamethasone (VRD), bortezomib+doxorubicin+dexamethasone (PAD), bortezomib+thalidomide+dexamethasone (VTD),bortezomib+pomadomide+dexamethasone (VPD), or carfilzomib+lenalidomide+dexamethasone (KRD), carfilzomib+thalidomide+dexamethasone (KTD),carfilzomib+pomalidomide+dexamethasone (KPD).

4. Must achieve at least partial response (PR) as defined by IMWG criteria afterbortezomib/carfilzomib-based initial therapy.

5. Eastern Cooperative Oncology Group (ECOG) 0-2.

Exclusion Criteria:

1. Received a bortezomib/carfilzomib-based triple-drug regimens as initial therapy lessthan 2 cycles.

2. Failure to have fully recovered (that is, less than or equal to [<=] Grade 1toxicity) from the reversible effects of prior chemotherapy.

3. Have documented diagnosis of other cancers prior to the diagnosis of MM, excludingsquamous and basal cell carcinomas of the skin, carcinoma in situ of the cervix orbreast, which is considered cured with minimal risk of recurrence within 3 years.

4. Has >=Grade 2 peripheral neuropathy (PN), or Grade 1 with pain on clinicalexamination at the time of enrollment.

5. Previously been treated with ixazomib or participated in a study with ixazomibwhether treated with ixazomib or not.

6. Have gastrointestinal (GI) disease or procedure that could interfere with the oralabsorption or tolerance of ixazomib including difficulty swallowing.

7. Have an active systemic infection, active hepatitis B or C virus infection, or knownhuman immunodeficiency virus positive.